Background: Ghrelin, an orexigenic hormone, has multiple favorable functions including protein anabolism enhancement, anti-inflammatory actions, and cardiovascular protection. A low plasma ghrelin level is associated with increased mortality in patients treated with hemodialysis (HD). However, it is unclear whether the plasma ghrelin level in HD patients correlates with the severity of gastric mucosal atrophy and Helicobacter pylori status. Methods: Seventy-eight maintenance HD patients and 51 non-dialysis patients with chronic kidney disease were evaluated for severity of gastric mucosal atrophy by gastroduodenoscopy and for H. pylori status using an anti-H. pylori-antibody and rapid urease test. Plasma acyl and des-acyl ghrelin levels were measured and their associations with relevant clinical parameters were investigated. Results: Des-acyl ghrelin level in HD patients was significantly higher than that in patients with kidney function preserved. Although acyl and des-acyl ghrelin levels were similar between current H. pylori positive and negative HD patients, both levels decreased significantly with the progress of endoscopic gastric mucosal atrophy in HD patients. Serum pepsinogen (PG) I level and PG I/II ratio decreased significantly according to the severity of atrophy in HD patients and positively significantly correlated with both ghrelin levels. Multiple regression analysis showed significant positive correlations between acyl ghrelin and PG I levels (β = 0.738, p < 0.001) and significant negative correlations between ghrelin and age, albumin, and creatinine levels. Conclusions: Gastric atrophy is the major determinant of ghrelin level in HD patients. Management practices, such as H. pylori eradication, before advanced atrophy may be required to prevent the decrease of ghrelin levels and improve the prognosis of HD patients.

Keywords:
Hemodialysis, Pepsinogen, Des-acyl ghrelin, Acyl ghrelin, Helicobacter pylori
1.
Pradhan G, Samson SL, Sun Y: Ghrelin: much more than a hunger hormone. Curr Opin Clin Nutr Metab Care 2013;16:619-624.
2.
Akamizu T, Kangawa K: Ghrelin for cachexia. J Cachexia Sarcopenia Muscle 2010;1:169-176.
3.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-660.
4.
Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S, Shirakami G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, Kangawa K, Nakao K: Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001;86:4753-4758.
5.
Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K: Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle 2011;2:9-25.
6.
Carrero JJ, Nakashima A, Qureshi AR, Lindholm B, Heimbürger O, Bárány P, Stenvinkel P: Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int 2011;79:749-756.
7.
Chou CC, Bai CH, Tsai SC, Wu MS: Low serum acylated ghrelin levels are associated with the development of cardiovascular disease in hemodialysis patients. Intern Med 2010;49:2057-2064.
8.
Wynne K, Giannitsopoulou K, Small CJ, Patterson M, Frost G, Ghatei MA, Brown EA, Bloom SR, Choi P: Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 2005;16:2111-2118.
9.
Ashby DR, Ford HE, Wynne KJ, Wren AM, Murphy KG, Busbridge M, Brown EA, Taube DH, Ghatei MA, Tam FW, Bloom SR, Choi P: Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int 2009;76:199-206.
10.
Mak RH, Cheung WW: Is ghrelin a biomarker for mortality in end-stage renal disease? Kidney Int 2011;79:697-699.
11.
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
12.
Sugimoto M, Sakai K, Kita M, Imanishi J, Yamaoka Y: Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney Int 2009;75:96-103.
13.
Sugimoto M, Yamaoka Y: Review of Helicobacter pylori infection and chronic renal failure. Ther Apher Dial 2011;15:1-9.
14.
Osawa H, Nakazato M, Date Y, Kita H, Ohnishi H, Ueno H, Shiiya T, Satoh K, Ishino Y, Sugano K: Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab 2005;90:10-16.
15.
Tsujita M, Goto N, Yamamoto T, Hiramitsu T, Nanmoku K, Inaguma D, Takeda A, Kobayashi T, Tominaga Y, Morozumi K, Uchida K, Watarai Y: How to estimate kidney function in kidney transplant recipients with mild to moderate kidney impairment: comparison of estimated glomerular filtration (eGFR) values between creatinine-based GFR equations and cystatin C-based GFR equations for Japanese population. Clin Exp Nephrol 2014;18:130-134.
16.
Kimura K, Takemoto T: An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969;1:87-97.
17.
Miki K, Ichinose M, Ishikawa KB, Yahagi N, Matsushima M, Kakei N, Tsukada S, Kido M, Ishihama S, Shimizu Y, et al: Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993;84:1086-1090.
18.
Shinzato T, Nakai S, Fujita Y, Takai I, Morita H, Nakane K, Maeda K: Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations. Nephron 1994;67:280-290.
19.
Pérez-Fontan M, Cordido F, Rodríguez-Carmona A, Peteiro J, García-Naveiro R, García-Buela J: Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 2004;19:2095-2100.
20.
Rodriguez Ayala E, Pecoits-Filho R, Heimbürger O, Lindholm B, Nordfors L, Stenvinkel P: Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol Dial Transplant 2004;19:421-426.
21.
ten Kate RW, Pals G, Pronk JC, Bank RA, Eriksson AW, Donker AJ, Meuwissen SG: Renal handling of pepsinogens A and C in man. Clin Sci (Lond) 1988;75:649-654.
22.
Aydemir S, Borazan A, Acikgoz S, Ustundag Y, Yilmaz A: The effects of continuous ambulatory peritoneal dialysis and hemodialysis on serum pepsinogen concentrations in patients with chronic renal failure. Tohoku J Exp Med 2005;205:263-268.
23.
Tamura H, Tokushima H, Murakawa M, Matsumura O, Itoyama S, Mitarai T, Isoda K: Influences of Helicobacter pylori on serum pepsinogen concentrations in dialysis patients. Nephrol Dial Transplant 1999;14:113-117.
24.
Araki H, Miyazaki R, Matsuda T, Gejyo F, Koni I: Significance of serum pepsinogens and their relationship to Helicobacter pylori infection and histological gastritis in dialysis patients. Nephrol Dial Transplant 1999;14:2669-2675.
25.
Schoonjans R, Van VB, Vandamme W, Van HN, Verdievel H, Vanholder R, Lameire N, De VM: Dyspepsia and gastroparesis in chronic renal failure: the role of Helicobacter pylori. Clin Nephrol 2002;57:201-207.
26.
Strid H, Simrén M, Stotzer PO, Abrahamsson H, Bjornsson ES: Delay in gastric emptying in patients with chronic renal failure. Scand J Gastroenterol 2004;39:516-520.
27.
Kovesdy CP, Kalantar-Zadeh K: Why is protein-energy wasting associated with mortality in chronic kidney disease? Semin Nephrol 2009;29:3-14.
28.
Chang CC, Hung CH, Yen CS, Hwang KL, Lin CY: The relationship of plasma ghrelin level to energy regulation, feeding and left ventricular function in non-diabetic haemodialysis patients. Nephrol Dial Transplant 2005;20:2172-2177.
29.
Bossola M, Scribano D, Colacicco L, Tavazzi B, Giungi S, Zuppi C, Luciani G, Tazza L: Anorexia and plasma levels of free tryptophan, branched chain amino acids, and ghrelin in hemodialysis patients. J Ren Nutr 2009;19:248-255.
30.
Sakao Y, Ojima T, Yasuda H, Hashimoto S, Hasegawa T, Iseki K, Tsubakihara Y, Kato A: Serum creatinine modifies associations between body mass index and mortality and morbidity in prevalent hemodialysis patients. PLoS One 2016;11:e0150003.
31.
Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K: Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15:1-20.
32.
Ando T, Mizuno S, Ishida T, Kondo Y, Miki I, Yoshida M, Azuma T, Ishikawa T, Takagi T, Yagi N, Kokura S, Naito Y, Yoshikawa T, Asakawa A, Inui A: Plasma ghrelin isoforms and gastric ghrelin O-acyltransferase expression are influenced by Helicobacter pylori status. Nutrition 2012;28:967-972.
33.
Jang EJ, Park SW, Park JS, Park SJ, Hahm KB, Paik SY, Sin MK, Lee ES, Oh SW, Park CY, Baik HW: The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. J Gastroenterol Hepatol 2008;23(suppl 2):S278-S285.
34.
Francois F, Roper J, Joseph N, Pei Z, Chhada A, Shak JR, de Perez AZ, Perez-Perez GI, Blaser MJ: The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. BMC Gastroenterol 2011;11:37.
35.
Aguilera A, Codoceo R, Bajo MA, Diéz JJ, del Peso G, Pavone M, Ortiz J, Valdez J, Cirugeda A, Fernández-Perpén A, Sánchez-Tomero JA, Selgas R: Helicobacter pylori infection: a new cause of anorexia in peritoneal dialysis patients. Perit Dial Int 2001;21(suppl 3):S152-S156.
36.
Gupta RK, Kuppusamy T, Patrie JT, Gaylinn B, Liu J, Thorner MO, Bolton WK: Association of plasma des-acyl ghrelin levels with CKD. Clin J Am Soc Nephrol 2013;8:1098-1105.
37.
Porporato PE, Filigheddu N, Reano S, Ferrara M, Angelino E, Gnocchi VF, Prodam F, Ronchi G, Fagoonee S, Fornaro M, Chianale F, Baldanzi G, Surico N, Sinigaglia F, Perroteau I, Smith RG, Sun Y, Geuna S, Graziani A: Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest 2013;123:611-622.
38.
Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y, Meguid MM, Kasuga M: Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 2005;54:18-24.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.